Price movement over the last 24 hours
Agilent Technologies Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Agilent Technologies Inc trades at $129 (market cap $37.04B), while ProShares UltraPro Short QQQ ETF trades at $40.66. The key difference: Agilent Technologies Inc pays a 0.78% dividend while ProShares UltraPro Short QQQ ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| A | SQQQ | |
|---|---|---|
Market Cap | $37.04B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $157.20 | $97.65 |
52-Week Low | $110.24 | $36.31 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
SQQQ (ProShares UltraPro Short QQQ ETF) declined 4.18% to $38.28, reflecting its bearish inverse leverage strategy against the Nasdaq-100. Technical indicators show a predominantly bearish signal with moving averages indicating strong selling pressure. The ETF's structure as a daily -3x leveraged product creates inherent decay risks, with historical data showing significant long-term value erosion. Recent news highlights concerns about SQQQ's suitability as a long-term investment vehicle.
SQQQ faces structural headwinds from daily reset mechanisms that compound losses in rising markets. While potentially useful for short-term tactical bearish bets, the ETF's design makes it unsuitable for buy-and-hold strategies. Investors seeking Nasdaq-100 exposure should consider the significant risks of value decay and timing sensitivity inherent in leveraged inverse products.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →